Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis ; PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF...

Related Keywords

United States ,Turkey ,Philadelphia ,Pennsylvania ,Brazil ,University Of Pennsylvania ,Canada ,Dolan Sondhi ,William Chou ,Mike Beyer ,Stuart Henderson ,Corporate Governance Committee ,Passage Bio Inc ,Development Rd Expenses ,Exchange Commission ,Nasdaq ,Professor Of Research ,University Of Pennsylvania Gene Therapy Program ,Sam Brown Inc ,Healthcare Communications ,Genetic Medicine ,Weill Cornell Medicine ,Corporate Governance ,Gene Therapy Program ,Private Securities Litigation Reform Act ,Risk Factors ,Months Ended June ,Markets ,